domperidone has been researched along with Indigestion in 67 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized, double-blind, double-dummy, positive-controlled study compared the efficacy and safety of cinitapride (1 mg) and domperidone (10 mg) tid for 4 weeks in 383 consecutive patients with mild to moderate, postprandial distress syndrome-predominant dyspeptic symptoms according to Rome III criteria." | 9.19 | Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. ( Chen, J; Ding, Y; Du, Y; Gao, J; Gong, L; Guo, J; Li, Z; Luo, H; Song, X; Su, T; Tian, D; Wang, B; Wang, S; Xie, W; Xu, J; Zhang, Z; Zou, D; Zuo, C, 2014) |
| "Both the medical device and domperidone significantly improved gastrointestinal symptoms and quality of life in subjects with functional dyspepsia, not showing significant difference in efficacy." | 9.15 | [Comparison of a new medical device with domperidone in functional dyspepsia: a randomized, cross-over, controlled study]. ( Covino, M; Fonnesu, C; Gallo, A; Gasbarrini, G; Giovinale, M; Montalto, M, 2011) |
| "To study the efficacy and safety of combined therapy of compound azintamid and domperidone in functional dyspepsia." | 9.15 | [Combination therapy of azintamid and domperidone in functional dyspepsia: a randomised, double-blind, placebo-controlled trial]. ( Li, Q; Wang, DM; Wang, XD; Wang, ZG; Xu, L; Zhao, L, 2011) |
| "1%) exhibited nocturnal dyspeptic symptoms with increased duodenogastric bile reflux time (intragastric bilirubin absorbance > 0." | 9.14 | Effect of domperidone therapy on nocturnal dyspeptic symptoms of functional dyspepsia patients. ( Cao, ZJ; Chen, SL; Fang, JY; Ji, JR; Mo, JZ; Xiao, SD; Xu, P, 2010) |
| "Levosulpiride, a dopaminergic antagonist was compared in a double-blind randomized study with domperidone for treatment of functional dyspepsia in 50 patients divided into two groups of 25 subjects each." | 9.07 | [Levosulpiride versus domperidone in the treatment of functional dyspepsia]. ( Blasi, A; Brogna, A; Catanzaro, R; Mangiameli, A; Sofia, M, 1994) |
| "A double-blind, placebo-controlled trial was performed to determine the therapeutic efficacy of cisapride in patients with refractory functional dyspepsia." | 9.07 | Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. ( De Nutte, N; Gooris, JP; Van Eeghem, P; Van Outryve, M, 1993) |
| "The anti-emetic effects of domperidone were evaluated under double-blind conditions in twenty-four patients with acute vomiting randomly assigned to treatment either with 10 mg i." | 9.05 | Double-blind evaluation of domperidone in acute vomiting and dyspeptic disorders. ( Agorastos, I; Goulis, G; Kaprinis, I; Zissis, NP, 1981) |
| "To evaluate the therapeutic effects of itopride vs other drugs (placebo, domperidone, mosapride) for functional dyspepsia (FD)." | 8.88 | Itopride therapy for functional dyspepsia: a meta-analysis. ( Fan, YH; Huang, X; Lv, B; Meng, LN; Zhang, S, 2012) |
| "Both cisapride and domperidone seem to be efficacious in functional dyspepsia, although this conclusion is largely based on global assessment by the investigator, which may not be an optimal outcome measure." | 8.81 | Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. ( Jones, MJ; Talley, NJ; Veldhuyzen van Zanten, SJ; Verlinden, M, 2001) |
| "Functional dyspepsia (FD) is a common gastrointestinal disease, for which domperidone is one of the most commonly used drugs." | 7.81 | Association between polymorphism of dopamine D2 receptor genes and therapeutic effect of domperidone in functional dyspepsia. ( Ma, H; Mou, Y; Xiang, Z; Xu, CF, 2015) |
| "Cisapride was more effective than domperidone in the REFLUX-Group." | 6.68 | Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride. ( Guyot, J; Halter, F; Hammer, B; Miazza, BM; Staub, P, 1997) |
| "Domperidone is a dopamine antagonist that does not readily enter the central nervous system." | 6.36 | Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. ( Avery, GS; Brogden, RN; Carmine, AA; Heel, RC; Speight, TM, 1982) |
| "Since the previous network meta-analysis assessing the efficacy of prokinetics for functional dyspepsia (FD), there have been a number of new studies and cinitapride is a new prokinetic agent for FD." | 5.41 | Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis. ( Li, Y; Liu, H; Qi, Q; Wang, N, 2023) |
| "This randomized, double-blind, double-dummy, positive-controlled study compared the efficacy and safety of cinitapride (1 mg) and domperidone (10 mg) tid for 4 weeks in 383 consecutive patients with mild to moderate, postprandial distress syndrome-predominant dyspeptic symptoms according to Rome III criteria." | 5.19 | Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. ( Chen, J; Ding, Y; Du, Y; Gao, J; Gong, L; Guo, J; Li, Z; Luo, H; Song, X; Su, T; Tian, D; Wang, B; Wang, S; Xie, W; Xu, J; Zhang, Z; Zou, D; Zuo, C, 2014) |
| "To observe the therapeutic effect of Modified Banxia Houpo Decoction (MBHD) in treating patients with functional dyspepsia (FD) accompanied with psychological factors, and to compare it with Domperidone, Neurostan, and Domperidone + Neurostan." | 5.17 | [Randomized controlled trial of modified banxia houpo decoction in treating functional dyspepsia patients with psychological factors]. ( Li, Y; Xiao, L, 2013) |
| "Both the medical device and domperidone significantly improved gastrointestinal symptoms and quality of life in subjects with functional dyspepsia, not showing significant difference in efficacy." | 5.15 | [Comparison of a new medical device with domperidone in functional dyspepsia: a randomized, cross-over, controlled study]. ( Covino, M; Fonnesu, C; Gallo, A; Gasbarrini, G; Giovinale, M; Montalto, M, 2011) |
| "To study the efficacy and safety of combined therapy of compound azintamid and domperidone in functional dyspepsia." | 5.15 | [Combination therapy of azintamid and domperidone in functional dyspepsia: a randomised, double-blind, placebo-controlled trial]. ( Li, Q; Wang, DM; Wang, XD; Wang, ZG; Xu, L; Zhao, L, 2011) |
| "1%) exhibited nocturnal dyspeptic symptoms with increased duodenogastric bile reflux time (intragastric bilirubin absorbance > 0." | 5.14 | Effect of domperidone therapy on nocturnal dyspeptic symptoms of functional dyspepsia patients. ( Cao, ZJ; Chen, SL; Fang, JY; Ji, JR; Mo, JZ; Xiao, SD; Xu, P, 2010) |
| "The effects on gastric emptying and gastrointestinal symptoms of treatment with cisapride alone and in combination with domperidone were investigated in 25 patients with chronic idiopathic dyspepsia." | 5.07 | Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients. ( Iishi, H; Nakaizumi, A; Okuda, S; Tatsuta, M, 1992) |
| "A double-blind, placebo-controlled trial was performed to determine the therapeutic efficacy of cisapride in patients with refractory functional dyspepsia." | 5.07 | Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. ( De Nutte, N; Gooris, JP; Van Eeghem, P; Van Outryve, M, 1993) |
| "Levosulpiride, a dopaminergic antagonist was compared in a double-blind randomized study with domperidone for treatment of functional dyspepsia in 50 patients divided into two groups of 25 subjects each." | 5.07 | [Levosulpiride versus domperidone in the treatment of functional dyspepsia]. ( Blasi, A; Brogna, A; Catanzaro, R; Mangiameli, A; Sofia, M, 1994) |
| "The effects of domperidone, a peripherally acting dopamine antagonist, were compared with those of placebo in a double-blind randomized study in 16 patients with idiopathic gastric stasis, chronic symptoms of "nonulcer dyspepsia" (including nausea, vomiting, and abdominal pain), and altered gastroduodenal motility." | 5.06 | Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study. ( Clench, MH; Davis, RH; Mathias, JR, 1988) |
| "The anti-emetic effects of domperidone were evaluated under double-blind conditions in twenty-four patients with acute vomiting randomly assigned to treatment either with 10 mg i." | 5.05 | Double-blind evaluation of domperidone in acute vomiting and dyspeptic disorders. ( Agorastos, I; Goulis, G; Kaprinis, I; Zissis, NP, 1981) |
| "To evaluate the therapeutic effects of itopride vs other drugs (placebo, domperidone, mosapride) for functional dyspepsia (FD)." | 4.88 | Itopride therapy for functional dyspepsia: a meta-analysis. ( Fan, YH; Huang, X; Lv, B; Meng, LN; Zhang, S, 2012) |
| "Both cisapride and domperidone seem to be efficacious in functional dyspepsia, although this conclusion is largely based on global assessment by the investigator, which may not be an optimal outcome measure." | 4.81 | Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. ( Jones, MJ; Talley, NJ; Veldhuyzen van Zanten, SJ; Verlinden, M, 2001) |
| "Based on these data both treatments are significantly more effective than placebo in the symptomatic treatment of non-ulcer dyspepsia, with gastroprokinetics (cisapride, domperidone) being more effective than histamine H2-receptor antagonists (cimetidine, ranitidine)." | 4.81 | Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. ( Allescher, HD; Böckenhoff, A; Hartung, J; Knapp, G; Wienbeck, M, 2001) |
| "For the drug treatment of gastroparesis, domperidone, metoclopramide and cisapride may be prescribed as prokinetics." | 4.80 | [Treatment of severely delayed gastric emptying]. ( Gooszen, HG; Samsom, M, 2000) |
| " These pharmacological differences have clinical relevance: metoclopramide and domperidon could not consistently prove efficacy in functional dyspepsia and GORD." | 4.79 | [Pharmacologic and clinical differentiation of prokinetic drugs]. ( Greving, I; May, B, 1996) |
| "The authors describe the gastro-kinetic drugs that act on functional dyspepsia including metoclopramide, domperidone, clebopride cisapride." | 4.78 | [Therapy of non-ulcer dyspepsia]. ( Cortese, I; Maselli, MA, 1990) |
| "Domperidone, a peripheral D2 dopamine receptor antagonist, has efficacy for treatment of nausea, dyspepsia, and gastroparesis." | 3.85 | Domperidone is Commonly Prescribed With QT-Interacting Drugs: Review of a Community-based Practice and a Postmarketing Adverse Drug Event Reporting Database. ( Alexoff, A; Ehrenpreis, ED; Roginsky, G; Smith, DG, 2017) |
| "Functional dyspepsia (FD) is a common gastrointestinal disease, for which domperidone is one of the most commonly used drugs." | 3.81 | Association between polymorphism of dopamine D2 receptor genes and therapeutic effect of domperidone in functional dyspepsia. ( Ma, H; Mou, Y; Xiang, Z; Xu, CF, 2015) |
| "Domperidone is a dopamine antagonist that has recently been released in Canada." | 3.76 | Domperidone, a new dopamine antagonist. ( Champion, MC; Hartnett, M; Yen, M, 1986) |
| " This study investigated the correlation between clinical improvement and quality of life after 12 months of treatment with cisapride or domperidone in patients with severe dyspepsia." | 3.69 | Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. ( Abell, TL; Cutts, TF; Karas, JG; Kuns, J, 1996) |
| "Twenty-four patients with non-ulcer dyspepsia (NUD) were recruited for gastric emptying study of liquid meal before and after 1 week's treatment with domperidone (80 mg in 19, 40 mg in 2, dropout 1 and excluded 2)." | 3.68 | Liquid meal emptying in non-ulcer dyspepsia: a study in 22 Thai patients. ( Keowkarnkar, W; Ovartlarnporn, B; Ratanalert, S, 1992) |
| "The incidence of dyspepsias and emesis occurring either as accompanying symptoms of gynaecological operations or as independent clinical conditions, therapeutic means for controlling these conditions and the mechanism of action and clinical usefulness of the dopamine antagonist domperidone have been discussed." | 3.67 | Use of peripheral dopamine antagonist (Motilium) in the treatment of dyspeptic complaints of different origin and in nausea, vomiting. ( Sásdi, A, 1989) |
| " No serious adverse events occurred in either group." | 3.30 | Efficacy and Safety of a Persian Medicine Formula on Functional Dyspepsia Symptoms: A Randomized Double-Blind Active-Control Clinical Trial. ( Azimi, M; Cramer, H; Iraji, A; Pasalar, M; Raeiszadeh, M; Zahedi, MJ, 2023) |
| "Cisapride was more effective than domperidone in the REFLUX-Group." | 2.68 | Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride. ( Guyot, J; Halter, F; Hammer, B; Miazza, BM; Staub, P, 1997) |
| "Dyspepsia is a common condition associated with gastrointestinal (GI) disease." | 2.58 | Prokinetics for functional dyspepsia. ( Bollegala, NP; Khanna, R; Leontiadis, GI; Moayyedi, P; Pittayanon, R; Yuan, Y, 2018) |
| "Dyspepsia is most optimally defined as pain or discomfort centred in the upper abdomen." | 2.40 | Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on Functional Dyspepsia. ( Fock, KM; Goh, KL; Lam, SK; Talley, NJ, 1998) |
| "Dyspepsia affects one in four Australians; of those who present in general practice, the majority will have functional or non-ulcer dyspepsia, with no structural explanation for their symptoms." | 2.39 | Modern management of dyspepsia. ( Talley, NJ, 1996) |
| "Domperidone is a dopamine antagonist that does not readily enter the central nervous system." | 2.36 | Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. ( Avery, GS; Brogden, RN; Carmine, AA; Heel, RC; Speight, TM, 1982) |
| "Functional dyspepsia is one of the most common functional disorders of the gastrointestinal tract, which resulted from impaired motor skills, visceral hypersensitivity, increased mucosal permeability, disorders of the autonomic nervous system, etc." | 1.62 | [Rational treatment of patients with functional dyspepsia]. ( Kazakov, AS; Nasretdinova, EK; Ushkalova, EA; Zyryanov, SK, 2021) |
| "Fatigue is seen in many medical conditions." | 1.38 | Fatigue: a prevalent symptom in gastroparesis. ( Cherian, D; Paladugu, S; Parkman, HP; Pathikonda, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (26.87) | 18.7374 |
| 1990's | 20 (29.85) | 18.2507 |
| 2000's | 9 (13.43) | 29.6817 |
| 2010's | 16 (23.88) | 24.3611 |
| 2020's | 4 (5.97) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, SM | 1 |
| Dai, ZQ | 1 |
| Wu, X | 2 |
| Li, MM | 1 |
| Liao, X | 1 |
| Kazakov, AS | 1 |
| Zyryanov, SK | 1 |
| Ushkalova, EA | 1 |
| Nasretdinova, EK | 1 |
| Azimi, M | 1 |
| Zahedi, MJ | 1 |
| Raeiszadeh, M | 1 |
| Iraji, A | 1 |
| Cramer, H | 1 |
| Pasalar, M | 1 |
| Qi, Q | 1 |
| Wang, N | 1 |
| Liu, H | 1 |
| Li, Y | 2 |
| Yang, YJ | 1 |
| Bang, CS | 1 |
| Baik, GH | 1 |
| Park, TY | 1 |
| Shin, SP | 1 |
| Suk, KT | 1 |
| Kim, DJ | 1 |
| Caviglia, GP | 1 |
| Sguazzini, C | 1 |
| Cisarò, F | 1 |
| Ribaldone, DG | 1 |
| Rosso, C | 1 |
| Fagoonee, S | 1 |
| Smedile, A | 1 |
| Saracco, GM | 1 |
| Astegiano, M | 1 |
| Pellicano, R | 1 |
| Pittayanon, R | 1 |
| Yuan, Y | 1 |
| Bollegala, NP | 1 |
| Khanna, R | 1 |
| Leontiadis, GI | 1 |
| Moayyedi, P | 1 |
| Vijayvargiya, P | 1 |
| Camilleri, M | 1 |
| Chedid, V | 1 |
| Mandawat, A | 1 |
| Erwin, PJ | 1 |
| Murad, MH | 1 |
| Xiao, L | 1 |
| Du, Y | 1 |
| Su, T | 1 |
| Song, X | 1 |
| Gao, J | 1 |
| Zou, D | 1 |
| Zuo, C | 1 |
| Xie, W | 1 |
| Wang, B | 1 |
| Zhang, Z | 2 |
| Xu, J | 1 |
| Tian, D | 1 |
| Luo, H | 1 |
| Wang, S | 1 |
| Chen, J | 1 |
| Guo, J | 1 |
| Gong, L | 1 |
| Ding, Y | 1 |
| Li, Z | 1 |
| Lan, L | 1 |
| Zeng, F | 1 |
| Liu, GJ | 1 |
| Ying, L | 1 |
| Liu, M | 1 |
| Liang, FR | 1 |
| Xiang, Z | 1 |
| Ma, H | 1 |
| Mou, Y | 1 |
| Xu, CF | 1 |
| Ehrenpreis, ED | 1 |
| Roginsky, G | 1 |
| Alexoff, A | 1 |
| Smith, DG | 1 |
| Zhou, GY | 1 |
| Zhou, GS | 1 |
| Jian-hong, J | 1 |
| Chen, SL | 1 |
| Ji, JR | 1 |
| Xu, P | 1 |
| Cao, ZJ | 1 |
| Mo, JZ | 1 |
| Fang, JY | 1 |
| Xiao, SD | 1 |
| Gallo, A | 1 |
| Giovinale, M | 1 |
| Fonnesu, C | 1 |
| Covino, M | 1 |
| Montalto, M | 1 |
| Gasbarrini, G | 1 |
| Zhao, L | 2 |
| Xu, L | 1 |
| Li, Q | 1 |
| Wang, XD | 1 |
| Wang, DM | 1 |
| Wang, ZG | 1 |
| Cherian, D | 1 |
| Paladugu, S | 1 |
| Pathikonda, M | 1 |
| Parkman, HP | 1 |
| Zhao, S | 1 |
| Sha, H | 1 |
| Li, ZY | 1 |
| Ren, CS | 1 |
| Hondeghem, LM | 1 |
| Huang, X | 1 |
| Lv, B | 1 |
| Zhang, S | 1 |
| Fan, YH | 1 |
| Meng, LN | 1 |
| Sawant, P | 1 |
| Das, HS | 1 |
| Desai, N | 1 |
| Kalokhe, S | 1 |
| Patil, S | 1 |
| Gan, AP | 1 |
| Ang, TL | 1 |
| Fock, KM | 2 |
| Teo, EK | 1 |
| Chan, YH | 1 |
| Ng, TM | 1 |
| Chua, TS | 1 |
| Tan, JY | 1 |
| Hiyama, T | 1 |
| Yoshihara, M | 1 |
| Matsuo, K | 1 |
| Kusunoki, H | 1 |
| Kamada, T | 1 |
| Ito, M | 1 |
| Tanaka, S | 1 |
| Nishi, N | 1 |
| Chayama, K | 1 |
| Haruma, K | 1 |
| Valenzuela, JE | 1 |
| Dooley, CP | 1 |
| Brogden, RN | 1 |
| Carmine, AA | 1 |
| Heel, RC | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Agorastos, I | 1 |
| Zissis, NP | 1 |
| Kaprinis, I | 1 |
| Goulis, G | 1 |
| Gnauen, H | 1 |
| De Loose, F | 1 |
| Jia, B | 1 |
| Mangiameli, A | 1 |
| Brogna, A | 1 |
| Catanzaro, R | 1 |
| Sofia, M | 1 |
| Blasi, A | 1 |
| Van Outryve, M | 1 |
| De Nutte, N | 1 |
| Van Eeghem, P | 1 |
| Gooris, JP | 1 |
| Talley, NJ | 3 |
| Cutts, TF | 1 |
| Abell, TL | 1 |
| Karas, JG | 1 |
| Kuns, J | 1 |
| May, B | 1 |
| Greving, I | 1 |
| Brignoli, R | 1 |
| Watkins, P | 1 |
| Halter, F | 2 |
| Staub, P | 1 |
| Hammer, B | 1 |
| Guyot, J | 1 |
| Miazza, BM | 1 |
| Lam, SK | 1 |
| Goh, KL | 1 |
| Samsom, M | 1 |
| Gooszen, HG | 1 |
| Veldhuyzen van Zanten, SJ | 1 |
| Jones, MJ | 1 |
| Verlinden, M | 1 |
| Allescher, HD | 1 |
| Böckenhoff, A | 1 |
| Knapp, G | 1 |
| Wienbeck, M | 1 |
| Hartung, J | 1 |
| Hongo, M | 1 |
| Satake, M | 1 |
| Jian, R | 1 |
| Ovartlarnporn, B | 1 |
| Ratanalert, S | 1 |
| Keowkarnkar, W | 1 |
| Varga, A | 1 |
| Lovas, J | 1 |
| Tatsuta, M | 1 |
| Iishi, H | 1 |
| Nakaizumi, A | 1 |
| Okuda, S | 1 |
| Iwanaga, Y | 1 |
| Miyashita, N | 1 |
| Mizutani, F | 1 |
| Morikawa, K | 1 |
| Kato, H | 1 |
| Ito, Y | 1 |
| Itoh, Z | 1 |
| Nijhawan, S | 1 |
| Rai, RR | 1 |
| Sharma, CM | 1 |
| Bradette, M | 1 |
| Pare, P | 1 |
| Douville, P | 1 |
| Morin, A | 1 |
| Canepa, G | 1 |
| Di Somma, C | 1 |
| Arnulfo, G | 1 |
| Frascio, M | 1 |
| Berti Riboli, E | 1 |
| Zahumenszky, Z | 1 |
| Farkas, E | 1 |
| Cortese, I | 1 |
| Maselli, MA | 1 |
| Harasawa, S | 1 |
| Takayasu, H | 1 |
| Sásdi, A | 1 |
| Garzia, G | 1 |
| Champion, MC | 2 |
| Davis, RH | 1 |
| Clench, MH | 1 |
| Mathias, JR | 1 |
| Takács, G | 1 |
| Udvardi, G | 1 |
| Mwakyusa, DH | 1 |
| Kis Csitári, I | 1 |
| Horváth, I | 1 |
| Huber, G | 1 |
| Hartnett, M | 1 |
| Yen, M | 1 |
| Sarin, SK | 1 |
| Sharma, P | 1 |
| Chawla, YK | 1 |
| Gopinath, P | 1 |
| Nundy, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Double-dummy, Active Drug Parallel Controlled, Multi-center Clinical Trial on the Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia[NCT01355276] | Phase 3 | 400 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Oral Domperidone for Relief of Gastrointestinal Disorders in Patients Who Failed Standard Therapy[NCT00761254] | 42 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to PI withdrew due to increased responsibilities in clinical department.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for domperidone and Indigestion
| Article | Year |
|---|---|
[Four Chinese patent medicines for regulating stomach for functional dyspepsia: a rapid health technology assessment].
Topics: Capsules; China; Chlorobenzenes; Domperidone; Drugs, Chinese Herbal; Dyspepsia; Humans; Nonprescript | 2022 |
Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis.
Topics: Adult; Bayes Theorem; Domperidone; Dyspepsia; Humans; Metoclopramide; Network Meta-Analysis; Randomi | 2023 |
Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Bayes Theorem; Benzamides; Benzyl Compounds | 2017 |
Prokinetics for functional dyspepsia.
Topics: Benzamides; Benzyl Compounds; Cisapride; Domperidone; Dyspepsia; Erythromycin; Gastrointestinal Agen | 2018 |
Effects of Promotility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis.
Topics: Breath Tests; Cisapride; Domperidone; Dopamine D2 Receptor Antagonists; Dyspepsia; Gastric Emptying; | 2019 |
Acupuncture for functional dyspepsia.
Topics: Acupuncture Therapy; Benzamides; Benzyl Compounds; Cisapride; Domperidone; Dyspepsia; Electroacupunc | 2014 |
Domperidone: limited benefits with significant risk for sudden cardiac death.
Topics: Action Potentials; Animals; Antiemetics; Death, Sudden, Cardiac; Domperidone; Dopamine Antagonists; | 2013 |
Itopride therapy for functional dyspepsia: a meta-analysis.
Topics: Antiemetics; Benzamides; Benzyl Compounds; Domperidone; Dyspepsia; Gastrointestinal Agents; Humans; | 2012 |
Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia.
Topics: Benzamides; Benzyl Compounds; Cisapride; Domperidone; Dopamine Antagonists; Dyspepsia; Gastrointesti | 2007 |
Dopamine antagonists in the upper gastrointestinal tract.
Topics: Diabetic Neuropathies; Digestive System; Domperidone; Dopamine Antagonists; Duodenum; Dyspepsia; Eso | 1984 |
Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.
Topics: Antiemetics; Domperidone; Dyspepsia; Endocrine Glands; Gastrointestinal Diseases; Hemodynamics; Huma | 1982 |
Modern management of dyspepsia.
Topics: Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Child; C | 1996 |
[Pharmacologic and clinical differentiation of prokinetic drugs].
Topics: Adult; Antiemetics; Child; Cisapride; Clinical Trials as Topic; Domperidone; Dopamine Antagonists; D | 1996 |
Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on Functional Dyspepsia.
Topics: Antiemetics; Asia; Cisapride; Disease Management; Domperidone; Dyspepsia; Endoscopy; Gastrointestina | 1998 |
[Treatment of severely delayed gastric emptying].
Topics: Cisapride; Diagnosis, Differential; Digestive System Surgical Procedures; Domperidone; Dyspepsia; El | 2000 |
Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis.
Topics: Cisapride; Domperidone; Dopamine Antagonists; Dyspepsia; Gastrointestinal Agents; Humans; Odds Ratio | 2001 |
Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies.
Topics: Cimetidine; Cisapride; Domperidone; Dyspepsia; Gastrointestinal Agents; Histamine H2 Antagonists; Hu | 2001 |
[Prokinetics of gastrointestinal system; its newer aspects with regard to motillity stimulants].
Topics: Acetylcholine; Benzamides; Cisapride; Domperidone; Dyspepsia; Gastrointestinal Agents; Gastrointesti | 2002 |
[Disorders of gastric emptying].
Topics: Cisapride; Diabetes Complications; Domperidone; Dyspepsia; Gastric Emptying; Gastroesophageal Reflux | 1992 |
[Therapy of non-ulcer dyspepsia].
Topics: Animals; Anti-Ulcer Agents; Antiemetics; Benzamides; Cisapride; Domperidone; Dyspepsia; Humans; Meto | 1990 |
Domperidone.
Topics: Colonic Diseases, Functional; Domperidone; Dyspepsia; Esophagitis, Peptic; Gastrointestinal Motility | 1988 |
Domperidone, a new dopamine antagonist.
Topics: Administration, Oral; Adult; Child; Clinical Trials as Topic; Domperidone; Dopamine Antagonists; Dys | 1986 |
24 trials available for domperidone and Indigestion
| Article | Year |
|---|---|
Efficacy and Safety of a Persian Medicine Formula on Functional Dyspepsia Symptoms: A Randomized Double-Blind Active-Control Clinical Trial.
Topics: Domperidone; Double-Blind Method; Dyspepsia; Humans; Iran; Quality of Life | 2023 |
[Randomized controlled trial of modified banxia houpo decoction in treating functional dyspepsia patients with psychological factors].
Topics: Adolescent; Adult; Anxiety Disorders; Depression; Domperidone; Drugs, Chinese Herbal; Dyspepsia; Fem | 2013 |
Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia.
Topics: Adolescent; Adult; Aged; Benzamides; Domperidone; Dopamine Antagonists; Dopamine D2 Receptor Antagon | 2014 |
[Clinical observation on transcutaneous electrical acupoint stimulation for treatment of functional dyspepsia].
Topics: Acupuncture Points; Adult; Aged; Benzamides; Domperidone; Dyspepsia; Female; Gastrointestinal Agents | 2009 |
Effect of domperidone therapy on nocturnal dyspeptic symptoms of functional dyspepsia patients.
Topics: Adult; Bile Reflux; Bilirubin; Diagnostic Techniques, Digestive System; Domperidone; Dopamine Antago | 2010 |
[Comparison of a new medical device with domperidone in functional dyspepsia: a randomized, cross-over, controlled study].
Topics: Adult; Cross-Over Studies; Domperidone; Drug Carriers; Drug Combinations; Dyspepsia; Female; Gastroi | 2011 |
[Combination therapy of azintamid and domperidone in functional dyspepsia: a randomised, double-blind, placebo-controlled trial].
Topics: Adolescent; Adult; Aged; Domperidone; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Fem | 2011 |
Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia.
Topics: Administration, Oral; Adolescent; Adult; Benzamides; Benzyl Compounds; Domperidone; Dose-Response Re | 2004 |
Clinical and psychological assessment on xinwei decoction for treating functional dyspepsia accompanied with depression and anxiety.
Topics: Adult; Anxiety Disorders; Depression; Domperidone; Dopamine Antagonists; Drugs, Chinese Herbal; Dysp | 2005 |
Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Cisapride; Clari | 2006 |
Double-blind evaluation of domperidone in acute vomiting and dyspeptic disorders.
Topics: Aged; Benzimidazoles; Clinical Trials as Topic; Domperidone; Double-Blind Method; Dyspepsia; Female; | 1981 |
[Domperidon in chronic dyspepsia. Results of an open pilot study and a multicentric crossover study with metoclopramide and placebo carried out by general practitioners].
Topics: Adult; Benzimidazoles; Domperidone; Double-Blind Method; Drug Evaluation; Dyspepsia; Female; Humans; | 1980 |
[Levosulpiride versus domperidone in the treatment of functional dyspepsia].
Topics: Adult; Benzamides; Domperidone; Dopamine Agents; Double-Blind Method; Dyspepsia; Female; Gastric Emp | 1994 |
Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Chronic Disease; Cisapride; Domperidone; Double-Blind Method; Dyspepsia; Fe | 1993 |
The Omega-Project--a comparison of two diagnostic strategies for risk- and cost-oriented management of dyspepsia.
Topics: Adult; Cisapride; Costs and Cost Analysis; Domperidone; Dopamine Antagonists; Double-Blind Method; D | 1997 |
Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Domperidone; Double-Blind Method; Dyspepsia; Female; Follow-Up | 1997 |
Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients.
Topics: Chronic Disease; Cisapride; Domperidone; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; | 1992 |
Visceral perception in health and functional dyspepsia. Crossover study of gastric distension with placebo and domperidone.
Topics: Adult; Domperidone; Double-Blind Method; Dyspepsia; Female; Humans; Pain; Pressure; Reference Values | 1991 |
[A retrospective study on the efficacy of the treatment of functional dyspepsia. An evaluation of 166 cases].
Topics: Adult; Antiemetics; Benzamides; Cisapride; Domperidone; Dyspepsia; Female; Humans; Male; Metoclopram | 1991 |
The role of a peripheral dopamine-antagonist (Motilium) in improving the tolerance to steroidal and non-steroidal anti-inflammatory agents.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Domperidone; Drug Tolerance; Dysp | 1990 |
[Single blind trial with domperidone in orally soluble granulates in patients with functional dyspepsia treated with H2 blockers].
Topics: Clinical Trials as Topic; Domperidone; Dyspepsia; Female; Histamine H2 Antagonists; Humans; Male; Mi | 1988 |
Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Domperidone; Double-Blind Method; Dyspepsia; Femal | 1988 |
Domperidone, a new dopamine antagonist.
Topics: Administration, Oral; Adult; Child; Clinical Trials as Topic; Domperidone; Dopamine Antagonists; Dys | 1986 |
Clinical trial on the effect of domperidone on non-ulcer dyspepsia.
Topics: Adolescent; Adult; Clinical Trials as Topic; Domperidone; Double-Blind Method; Dyspepsia; Female; Hu | 1986 |
22 other studies available for domperidone and Indigestion
| Article | Year |
|---|---|
[Rational treatment of patients with functional dyspepsia].
Topics: Antidepressive Agents, Tricyclic; Cisapride; Domperidone; Dyspepsia; Helicobacter Infections; Humans | 2021 |
Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test.
Topics: Adult; Amitriptyline; Benzamides; Breath Tests; Buspirone; Caprylates; Domperidone; Drug Evaluation; | 2017 |
Association between polymorphism of dopamine D2 receptor genes and therapeutic effect of domperidone in functional dyspepsia.
Topics: Adolescent; Adult; Aged; Alleles; Domperidone; Dopamine Antagonists; Dyspepsia; Female; Gene Frequen | 2015 |
Domperidone is Commonly Prescribed With QT-Interacting Drugs: Review of a Community-based Practice and a Postmarketing Adverse Drug Event Reporting Database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antiemetics; Domperidone; D | 2017 |
Fatigue: a prevalent symptom in gastroparesis.
Topics: Adult; Diagnostic Self Evaluation; Domperidone; Dopamine Antagonists; Dyspepsia; Fatigue; Female; Ga | 2012 |
Electrical bioimpedance gastric motility measurement based on an electrical-mechanical composite mechanism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Case-Control Studies; China; Domperidone; Dopamine A | 2012 |
[Domperidon--a new gastrokinetic and anti-emetic without central-nervous side effects].
Topics: Acetylcholine; Acetylcholinesterase; Antiemetics; Benzimidazoles; Domperidone; Dyspepsia; Enzyme Inh | 1980 |
[Drug therapy of gastrointestinal motility disorders].
Topics: Cisapride; Domperidone; Dyspepsia; Gastroesophageal Reflux; Gastroparesis; Humans; Metoclopramide; P | 1995 |
Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia.
Topics: Adult; Aged; Attitude to Health; Cisapride; Domperidone; Dyspepsia; Female; Gastrointestinal Agents; | 1996 |
Liquid meal emptying in non-ulcer dyspepsia: a study in 22 Thai patients.
Topics: Adult; Domperidone; Dyspepsia; Female; Gastric Emptying; Humans; Male; Prospective Studies | 1992 |
Some possible gynaecological indications for peripheral antidopamine therapy.
Topics: Adult; Climacteric; Domperidone; Drug Evaluation; Dyspepsia; Female; Gastrointestinal Diseases; Huma | 1992 |
Stimulatory effect of N-[4-[2-(dimethylamino)-ethoxy] benzyl]-3,4-dimethoxybenzamide hydrochloride (HSR-803) on normal and delayed gastrointestinal propulsion.
Topics: Acetaminophen; Administration, Oral; Animals; Benzamides; Benzyl Compounds; Cisapride; Dogs; Domperi | 1991 |
Domperidone induced galactorrhea.
Topics: Adolescent; Domperidone; Dyspepsia; Female; Galactorrhea; Humans | 1991 |
[Clinical effects of gastrointestinal-motility stimulating agents on non-ulcer dyspepsia].
Topics: Acetylcholine; Adenosine Triphosphate; Adult; Cisapride; Domperidone; Drug Therapy, Combination; Dys | 1990 |
Use of peripheral dopamine antagonist (Motilium) in the treatment of dyspeptic complaints of different origin and in nausea, vomiting.
Topics: Adolescent; Adult; Aged; Domperidone; Dyspepsia; Female; Genital Diseases, Female; Humans; Hyperemes | 1989 |
Management of dyspepsia: report of a working party.
Topics: Adult; Antacids; Bismuth; Cimetidine; Diagnosis, Differential; Domperidone; Dyspepsia; Histamine H2 | 1988 |
Effect of domperidone on postoperative vomiting and dyspepsia aggravated by operation.
Topics: Adult; Domperidone; Dyspepsia; Female; Humans; Middle Aged; Nausea; Postoperative Complications; Pre | 1988 |
Dopamine antagonist domperidone (Motilium) in everyday clinical practice.
Topics: Adult; Aged; Domperidone; Dyspepsia; Female; Humans; Male; Middle Aged; Nausea; Vomiting | 1988 |
Effects of domperidone in dyspepsia.
Topics: Adolescent; Adult; Aged; Domperidone; Dyspepsia; Female; Humans; Male | 1987 |
Use of peripheral dopamine receptor antagonist in gynaecology in certain borderline cases.
Topics: Climacteric; Domperidone; Dyspepsia; Female; Gastrointestinal Diseases; Humans; Migraine Disorders; | 1987 |
Observations with dopamine antagonist domperidone (Motilium) in controlling postoperative dyspepsias and vomiting.
Topics: Abdomen; Adult; Aged; Domperidone; Dyspepsia; Female; Humans; Male; Middle Aged; Postoperative Compl | 1987 |
Treatment of gastro-intestinal complaints accompanying menopause with Motilium film-coated tablet.
Topics: Adult; Climacteric; Domperidone; Dyspepsia; Female; Gastrointestinal Diseases; Humans; Middle Aged | 1987 |